Acasti to present gtx-104 pharmacokinetic comparison data at neurocritical care annual meeting

Princeton, n.j., aug. 09, 2023 (globe newswire) -- acasti pharma inc. (nasdaq: acst) ("acasti" or the "company"), a late-stage, biopharma company advancing gtx-104 its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced that a poster presenting a pharmacokinetic comparison of gtx-104 with oral nimodipine has been accepted for presentation at the 2023 neurocritical care society (ncs) annual meeting, to be held in phoenix, az august 15-18, 2023.
ACST Ratings Summary
ACST Quant Ranking